Benzinga | Dec 22, 2021 04:07PM EST

Microbot Medical Reports Initiation Of Search For US Clinical Sites For LIBERTY Robotic System

Microbot Medical Inc. (NASDAQ:MBOT) announced that it has and will continue to implement key initiatives that will prepare the LIBERTY(r) Robotic System for commercialization. In conjunction with recently announced design freeze, Dr. Eyal Morag, Microbot's Chief Medical Officer, traveled to the United States to establish a clinical infrastructure with multiple sites and leading physicians for the commencement of a human clinical trial, which is expected to commence in the second half of 2022.

"Our actions reflect an inflection point in LIBERTY's(r) developmental pathway and it is critical that we align our interests to ensure we successfully execute the value-enhancing catalysts in 2022, including the FDA pre-submission and the human clinical trial expected in the second half of 2022," commented Dr. Eyal Morag, Microbot's Chief Medical Officer. "My primary goal over the next few months is to leverage our resources and to educate the market on the clinical and economic benefits of the LIBERTY Robotic System to ensure future success in commercialization."